Contribution of beta-HPV infection and UV damage to rapid-onset cutaneous squamous cell carcinoma during BRAF-inhibition therapy

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2624-2634

  Cohen, Daniel N ^a   Lawson, Steven K ^a   Shaver, Aaron C ^a   Du, Liping ^b   Nguyen, Harrison P ^c   He, Qin ^c   Johnson, Douglas B ^b   Lumbang, Wilfred A ^d   Moody, Brent R ^e   Prescott, James L ^f   Chandra, Pranil K ^f   Boyd, Alan S ^a,d,g   Zwerner, Jeffrey P ^a,d   Robbins, Jason B ^a,d,h   Tyring, Stephen K ^c   Rady, Peter L ^c   Chappell, James D ^a   Shyr, Yu ^b   Infante, Jeffrey R ⁱ   Sosman, Jeffrey A ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e Heritage Medical Associates   (United States)

^f PathGroup   (United States)

^g PathologyCon sultants of America   (United States)

^h Pathology Associates of St Thomas   (United States)

ⁱ SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; TRAMETINIB; VEMURAFENIB; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; ADVANCED CANCER; AGED; ALK GENE; ARTICLE; BRAF INHIBITION THERAPY; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CKIT GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; EGFR GENE; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; FEMALE; GENE; GENE MUTATION; GENETIC PARAMETERS; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 111; HUMAN PAPILLOMAVIRUS TYPE 17; HUMAN PAPILLOMAVIRUS TYPE 38; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; MELANOMA; PAPILLOMAVIRUS INFECTION; PIK3CA GENE; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION INJURY; SKIN CARCINOMA; SKIN DISEASE; ULTRAVIOLET RADIATION; VIRUS ISOLATION; WART VIRUS; COMPLICATION; GENETICS; MIDDLE AGED; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOPHYSIOLOGY; RADIATION RESPONSE; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; VIROLOGY;

ADULT; AGED; CARCINOGENESIS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES; ULTRAVIOLET RAYS;

EID: 84942241318     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2667     Document Type: Article

References (58)

1. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemur-afenib. N Engl J Med 2012;366:707-14.
2. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012;379:1893-901.
3. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:1087-95.
4. Cohen DN, Chappell JD, Robbins JB. Squamous cell carcinoma in BRAF-inhibitor-treated melanoma patients. In abstracts presented at the 15th Joint Meeting of the International Society of Dermatopathology, March 14-15, San Diego, CA, USA. Amer J Dermatopath 2012;34:e55-72.
5. Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, et al. Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 2012;67: 1265-72.
6. Harvey NT, Millward M, Wood BA. Squamoproliferative lesions arising in the setting of BRAF inhibition. Am J Dermatopathol 2012;34:822-6.
7. Huang V, Hepper D, Anadkat M, Cornelius L. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012;148:628-33.
8. Cohen DN, Lumbang WA, Boyd AS, Sosman JA, Zwerner JP. Spindle cell squamous carcinoma during BRAF inhibitor therapy for advanced mela-noma:anaggressive secondary neoplasm ofundetermined biologic potential. JAMA Dermatol 2014;150:575-7.
9. Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, et al. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol 2013;31:e448-51.
10. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012;367:2316-21.
11. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
12. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: A case series. Ann Oncol 2013;24:530-7.
13. Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D, et al. Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 2013;18:314-22.
14. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013;24:1691-7.
15. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323-32.
16. Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol 2014;15:436-44.
17. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867-76.
18. Belum VR, Rosen AC, Jaimes N, Dranitsaris G, Pulitzer MP, Busam KJ, et al. Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. Cancer 2015;121:60-8.
19. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
20. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, deBraud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371:1877-88.
21. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014; 15:954-65.
22. Ziegler A, Jonason A, Simon J, Leffell D, Brash DE. Tumor suppressor gene mutations and photocarcinogenesis. Photochem Photobiol 1996;63: 432-5.
23. Popp S, Waltering S, Herbst C, Moll I, Boukamp P. UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 2002;99:352-60.
24. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. RAS mutations are associated with the development of cutaneous squa-mous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012;30:316-21.
25. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15.
26. Anforth R, Tembe V, Blumetti T, Fernandez-Penas P. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res 2012;25:569-72.
27. Cohen DN, Chappell JD, Robbins JB. Human papillomavirus mechanisms in squamous cell carcinomagenesis in BRAF-inhibitor treated melanoma patients (#110). In Carcinogenesis, Growth factors, and Cancer genetics, abstracts of the Society for Investigative Dermatology 72nd Annual Meeting, May 9-12, Raleigh, NC, USA. J Invest Derm 2012;132:S19-30.
28. White MK, Pagano JS, Khalili K. Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev 2014;27:463-81.
29. Sri JC, Dubina MI, Kao GF, Rady PL, Tyring SK, Gaspari AA. Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol 2012;66:292-311.
30. Anforth RM, Blumetti TC, Kefford RF, Sharma R, Scolyer RA, Kossard S, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012;167:1153-60.
31. Ko CJ, McNiff JM, Iftner A, Iftner T, Choi JN. Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae. J Am Acad Dermatol 2013;69:e95-6.
32. Dika E, Patrizi A, Venturoli S, Fanti PA, Barbieri D, Strammiello R, et al. Human papillomavirus evaluation ofvemurafenib induced skin epithelial tumors: a case series. Br J Dermatol 2015;172:540-2.
33. Quint KD, Genders RE, de Koning MN, Borgogna C, Gariglio M, Bouwes Bavinck JN, et al. Human beta-papillomavirus infection and keratinocyte carcinomas. J Pathol 2014;235:342-54.
34. Falchook GS, Rady P, Hymes S, Nguyen HP, Tyring SK, Prieto VG, et al. Merkel cell polyomavirus and HPV-17 associated with cutaneous squa-mous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol 2013;149:322-6.
35. Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, et al. Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res 2014;74:2238-45.
36. Hassel JC, Groesser L, Herschberger E, Weichert W, Hafner C. RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma. J Invest Dermatol 2015;135:636-9.
37. Resnick RM, Cornelissen MT, Wright DK, Eichinger GH, Fox HS, ter Schegget J, et al. Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers. J Natl Cancer Inst 1990;82:1477-84.
38. Fuessel-Haws AL, He Q, Rady PL, Zhang L, Grady J, Hughes TK, et al. Nested PCR with the PGMY09/11 and GP5(+)/6(+) primer sets improves detection of HPV DNA in cervical samples. J Virol Methods 2004;122:87-93.
39. Harwood CA, Spink PJ, Surentheran T, Leigh IM, de Villiers EM, McGregor JM, et al. Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts. J Clin Microbiol 1999;37:3545-55.
40. Forslund O, Ly H, Reid C, Higgins G. A broad spectrum of human papillomavirus types is present in the skin of Australian patients with non-melanoma skin cancers and solar keratosis. Br J Dermatol 2003; 149:64-73.
41. de Oliveira WR, He Q, Rady PL, Hughes TK, Neto CF, Rivitti EA, et al. HPV typing in Brazilian patients with epidermodysplasia verruciformis: high prevalence of EV-HPV 25. J Cutan Med Surg 2004;8:110-5.
42. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
43. Boyd AS, Annarella M, Rapini RP, Adler-Storthz K, Duvic M. False-positive polymerase chain reaction results for human papillomavirus in lichen planus. potential laboratory pitfalls of this procedure. J Am Acad Dermatol 1996;35:42-6.
44. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004;324:17-27.
45. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyoma-virus in human merkel cell carcinoma. Science 2008;319:1096-100.
46. Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, et al. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. eLife 2013;2:e00969.
47. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human pap-illomavirus detection by PCR. J Gen Virol 1995;76:1057-62.
48. Ekstrom J, Bzhalava D, Svenback D, Forslund O, Dillner J. High throughput sequencing reveals diversity of human papillomaviruses in cutaneous lesions. Int J Cancer 2011;129:2643-50.
49. Asgari MM, Kiviat NB, Critchlow CW, Stern JE, Argenyi ZB, Raugi GJ, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol 2008;128:1409-17.
50. Iannacone MR, Wang W, Stockwell HG, O'Rourke K, Giuliano AR, Sondak VK, et al. Sunlight exposure and cutaneous human papillomavirus seror-eactivity in basal cell and squamous cell carcinomas of the skin. J Infect Dis 2012;206:399-406.
51. Forslund O, Iftner T, Andersson K, Lindelof B, Hradil E, Nordin P, et al. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominates in squamous cell carcinoma. J Infect Dis 2007;196:876-83.
52. Plasmeijer EI, Neale RE, Buettner PG, de Koning MN, Ter Schegget J, Quint WG, et al. Betapapillomavirus infection profiles in tissue sets from cutaneous squamous cell-carcinoma patients. Int J Cancer 2010;126:2614-21.
53. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, Giarre M, et al. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 2003;77:2195-206.
54. Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, Grone HJ, et al. E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog 2011;7: e1002125.
55. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al. T antigen mutations are a human tumor-specific signature for merkel cell polyoma-virus. Proc Natl Acad Sci U S A 2008;105:16272-7.
56. Dworkin AM, Tseng SY, Allain DC, Iwenofu OH, Peters SB, Toland AE. Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol 2009;129: 2868-74.
57. Zaravinos A, Kanellou P, Spandidos DA. Viral DNA detection and RAS mutations in actinic keratosis and nonmelanoma skin cancers. Br J Der-matol 2010;162:325-31.
58. Mogha A, Fautrel A, Mouchet N, Guo N, Corre S, Adamski H, et al. Merkel cell polyomavirus small T antigen mRNA level is increased following in vivo UV-radiation. PLoS One 2010;5:e11423.